ClinicalTrials.gg
RecruitingNCT04997837Updated Aug 10, 2021

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

A Phase 3 interventional study of PD-1 inhibitor and Oxaliplatin in Gastric Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
433
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 319 studies testing Immune checkpoint inhibitors in Stomach Neoplasms — 139 open to participants now, 189 under way, 20 of them phase 3. A drug class: Immune checkpoint inhibitors · Stomach Neoplasms.

Planned enrollment
39th of 319
433 · median 50
Started
2021
with 35 others
Phase 3
31 of 319
12 open now
Primary completion
2027-07
later than 128 of 188 live
Registered
128th of 319
by date
Lead sponsor
16 of 319
Fudan University

Among the 319 studies testing Immune checkpoint inhibitors in Stomach Neoplasms, this one is the 39th largest by planned enrollment, is one of 36 that started in 2021, is one of 31 in phase 3, reaches primary completion later than 128 of the 188 other live ones, and was the 128th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

139 of the 319 studies testing Immune checkpoint inhibitors in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

134 more — sign in →

By country, each count listing its studies:

All 139 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 319 studies testing Immune checkpoint inhibitors in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or gastroesophageal junction adenocarcinoma. PD-1+CRT cohort: A total of 216 patients will receive 6 weeks of PD-1 inhibitors and chemotherapy, then receive concurrent chemoradiotherapy, followed by 6 weeks of PD-1 inhibitors and chemotherapy, finally receive maintenance treatment of PD-1 inhibitors until (maximum 1year after radiotherapy). CT cohort: A total of 217 patients will receive 6 months of chemotherapy. The disease-free survival(DFS), overall survival(OS) and adverse effects will be analyzed.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status (PS) score of 0 or 1
  • Patients with expected survival time more than 6 months
  • Patients after standard D2/R0 resection
  • Postoperative confirmed adenocarcinoma of the stomach or GEJ
  • Positive lymph nodes more than 7, stage pN3
  • Patients without distant (M0) or M1 with abdominal exfoliated cell detection positive (CY1P0)
  • Patients' physical condition and visceral function allows following therapy, including chemotherapy, chemoradiotherapy and inhibitor therapy.
  • Patients' blood routine and biochemical indicators should meet the following standard: ≥90g/L, ≥1.5*10\^9/L, ≥100*10\^9/L, \& AST≤2.5 U/L, TB ≤ 1.5 UNL, serum creatinine\<1 UNL.
  • Patients who are willing to obey regimens during the study.
  • Written is acquired before random entry, and patients should know that he/she has the right to quit, and following treatment won't be affected.
  • Patients are willing to provide samples of blood and tissue.

Exclusion criteria

Exclusion Criteria:

  • Patients with gross peritoneal (CY1P0 excluded) or distant metastasis.
  • Patients who has received any anti-tumor therapy before surgery.
  • Patients who had received radiotherapy for abdominal organs including stomach, liver, kidney, etc.
  • Patients who had active systematic diseases which need systematic treatment within 2 years before first medication in the study, substitutive therapy (such as thyroxine, insulin, etc) excluded.
  • Patients diagnosed with immunodeficiency, or was receiving systematic treatment or other therapy within 7 days before medication, physiological dose of glucocorticoid is allowed (≤10 mg/d prednison or equivalent medication)
  • Patients who have known severe allergic reaction (≥level 3) to monoclonal antibody, 5-FU, Oxaliplatin or any auxiliary material.
  • Patient diagnosed with other malignant tumor in the past 5 years, excluding radical basal cell carcinoma of the skin and/or radical resected carcinoma in situ.
  • Patient with severe vital organ failure.
  • Pregnant or lactation period
  • Patient with known mental illness or drug abuse that may influence compliance.
  • Patient with known infection, or active tuberculosis.
  • Untreated active
  • Patient with active infection
  • Uncontrolled complications
  • Other situations that might disturb study results and compliance.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
433 participants (estimated)

Study arms

  • Experimental
    PD-1 inhibitor and chemoradiotherapy

    PD-1 inhibitor+CapeOX/SOX/FOLFOX for 6 weeks, followed by chemoradiotherapy; 6 weeks of PD-1 inhibitor and CapeOX/SOX/FOLFOX for 6 weeks after chemoradiotherapy, followed by PD-1 inhibitor, till 12 months after chemoradiotherapy. PD-1 inhibitor Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W. Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator. Chemoradiotherapy Radiotherapy: 1.8 Gy/fx, 45-50.5Gy Chemotherapy: Capecitabine 625mg/m2 bid orally with radiotherapy; OR Tegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy.

    Drug: PD-1 inhibitor · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Tegafur-gimeracil-oteracil potassium · Drug: 5-FU · Radiation: Radiotherapy · Drug: Chemotherapy

  • Active comparator
    Chemotherapy

    Chemotherapy: CapeOx or SOX or FOLFOX therapy determined by investigator. CapeOX: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off. Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off. SOX: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off. Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off. FOLFOX: Oxaliplatin 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off. 5-FU 2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W.

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: Tegafur-gimeracil-oteracil potassium · Drug: 5-FU

Interventions

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.

  • CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off. FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.

  • CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.

  • DrugTegafur-gimeracil-oteracilStudies of Tegafur-gimeracil-oteracilTegafur-gimeracil-oteracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    FOLFOX:2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W

  • RadiationRadiotherapy

    1.8 Gy/Fx, 45-50.4 Gy

  • DrugChemotherapy

    Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. 3-year DFS rate

    Defined as the time from randomization to the date of first documented progression or death from any cause.

    Time frame: Up to 3 years

Secondary outcomes

  1. 3-year OS rate

    Defined as the time from randomization to death from any cause.

    Time frame: Up to 3 years

  2. 3-year local recurrence free survival rate

    Defined as the time from randomization to the date of first documented recurrence or death from any cause.

    Time frame: Up to 3 years

  3. Percentage of participants with treatment-related acute adverse events as assessed by CTCAE v5.0

    Time frame: Up to 28 days from last dose

  4. Quality of life as assessed by Quality of Life Scale (range 0-60)

    It evaluates the quality of life from 12 aspects, including appetite, mental status, sleep quality, fatigue, etc. The higher scores mean a better quality of life.

    Time frame: Through study completion, up to 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jul 2027, 72 months after the start.

Of 73 non-industry phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 144. This study's planned 72 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2021
First posted
Aug 10, 2021
StartActual
Jul 21, 2021
Primary completionEst.
Jul 21, 2027
CompletionEst.
Oct 21, 2027
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04997837
Lead sponsor
Fudan University
Responsible party
Zhen Zhang (Professor, Fudan University) — Principal investigator
First posted
Aug 10, 2021
Start date
Jul 21, 2021
Primary completion
Jul 21, 2027 (estimated)
Completion
Oct 21, 2027 (estimated)
Last update
Aug 10, 2021

Study contacts

Zhen Zhang, MD, PhD
Contact
zhen_zhang@fudan.edu.cn
18801735029
Zhen Zhang, MD,PhD
principal investigator · Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immune checkpoint inhibitors · Pembrolizumab · Nivolumab

Start the discussion